Company / Operating Cash Flow
Minerva Neurosciences, Inc. Operating Cash Flow History
FY2017-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$19.6M
FY2024
5-year range
-$43.4M / -$19.6M
FY2020-FY2024
Trend
+20.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 8 years, ranging from -$43M in FY2020 to $3M in FY2018.
Based on SEC 10-K filings.
-$20M in FY2024.
Improved from -$25M to -$20M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, operating cash flow increased 20.7% year-over-year.
- Peak operating cash flow was recorded in FY2018.
- Lowest operating cash flow in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -10.64 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$19.6M | +20.7% |
| FY2023 | -$24.6M | -0.2% |
| FY2022 | -$24.6M | +27.3% |
| FY2021 | -$33.8M | +22.1% |
| FY2020 | -$43.4M | -3.6% |
| FY2019 | -$41.9M | -1456.1% |
| FY2018 | $3.1M | +112.7% |
| FY2017 | -$24.3M | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026